TC |
Stat |
Stk |
Ins |
Fil |
+d |
+w |
+m |
+q |
+h |
+y |
avg |
|---|
Filing Date |
T Date |
Ticker |
Issuer | Inc | Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2/26/24 20:38 | 2/23/24 | RGEN | Repligen Corp | DE | Health | BioPrd | Biological Products, (No Diag | Bylund James | MA | O | COO | M.d | 89 | 94.33 | 0 | 1 | 7 | 14 | D | ||||||||||||||
2/26/24 20:38 | 2/23/24 | RGEN | Repligen Corp | DE | Health | BioPrd | Biological Products, (No Diag | Bylund James | MA | O | COO | S.d | -866 | 198.08 | 0 | -4 | -24 | 14 | D | ||||||||||||||
8/4/22 16:32 | 8/3/22 | RGEN | Repligen Corp | DE | Health | BioPrd | Biological Products, (No Diag | Bylund James | MA | O | COO | M.d | 189 | 94.33 | 0 | 2 | 26 | 10 | D | ||||||||||||||
8/4/22 16:32 | 8/3/22 | RGEN | Repligen Corp | DE | Health | BioPrd | Biological Products, (No Diag | Bylund James | MA | O | COO | S.d | -481 | 240.40 | 0 | -2 | -17 | 10 | D | ||||||||||||||
4/8/21 19:55 | 4/6/21 | RGEN | Repligen Corp | DE | Health | BioPrd | Biological Products, (No Diag | Bylund James | MA | O | SVP,Glob | S | -74 | 204.25 | 0 | 0 | -5 | 6 | D |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |